You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluoxymesterone
Accession NumberDB01185  (APRD00981)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionAn anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. [PubChem]
Structure
Thumb
Synonyms
11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one
17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone
17α-Methyl-9α-fluoro-11β-hydroxytesterone
9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one
9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone
Fluoximesterona
Fluoxymesteronum
Testosterone, 9-fluoro-11beta-hydroxy-17-methyl-
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Halotestintablet5 mgoralPfizer Canada Inc1962-12-312006-08-02Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Androxytablet10 mg/1oralUpsher Smith Laboratories Inc.1983-10-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ora-TestrylBristol-Myers Squibb
TestoralMidy
U-GonoUpjohn
UItandrenCiba
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9JU12S4YFY
CAS number76-43-7
WeightAverage: 336.4409
Monoisotopic: 336.210072999
Chemical FormulaC20H29FO3
InChI KeyInChIKey=YLRFCQOZQXIBAB-RBZZARIASA-N
InChI
InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
IUPAC Name
(1R,2S,10S,11S,14S,15S,17S)-1-fluoro-14,17-dihydroxy-2,14,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • Androgen-skeleton
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationIn males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.
PharmacodynamicsFluoxymesterone is a synthetic androgen, or male hormone, similar to testosterone. Fluoxymesterone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells.
Mechanism of actionFluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.
Related Articles
AbsorptionOral absorption is less than 44%.
Volume of distributionNot Available
Protein bindingVery high (99%) with 80% to sex hormone binding globulin, 19% to albumin.
Metabolism

Presence of 17-alpha alkyl group reduces susceptibility to hepatic enzyme degradation, which slows metabolism and allows oral administration. Inactivation of testosterone occurs primarily in the liver

Route of eliminationNot Available
Half life9.2 hours
ClearanceNot Available
ToxicitySide effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9633
Caco-2 permeable+0.8586
P-glycoprotein substrateSubstrate0.7505
P-glycoprotein inhibitor INon-inhibitor0.7583
P-glycoprotein inhibitor IINon-inhibitor0.87
Renal organic cation transporterNon-inhibitor0.8136
CYP450 2C9 substrateNon-substrate0.862
CYP450 2D6 substrateNon-substrate0.8773
CYP450 3A4 substrateSubstrate0.7669
CYP450 1A2 substrateNon-inhibitor0.9041
CYP450 2C9 inhibitorNon-inhibitor0.8159
CYP450 2D6 inhibitorNon-inhibitor0.9286
CYP450 2C19 inhibitorNon-inhibitor0.917
CYP450 3A4 inhibitorNon-inhibitor0.8354
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8585
Ames testNon AMES toxic0.8777
CarcinogenicityNon-carcinogens0.9242
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7028 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.943
hERG inhibition (predictor II)Non-inhibitor0.5784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Fluoxymesterone powder391.79USD g
Android 10 mg capsule11.35USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point265U.S. Patent 2,793,218 U.S. Patent 2,813,881
water solubility67.5 mg/LNot Available
logP2.38HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0452 mg/mLALOGPS
logP2.5ALOGPS
logP2.38ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity90.19 m3·mol-1ChemAxon
Polarizability36.63 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-006x-5951000000-4c37d94fe4ed0b343941View in MoNA
References
Synthesis Reference

U.S. Patent 2,793,218
U.S. Patent 2,813,881

General References
  1. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. [PubMed:17023534 ]
External Links
ATC CodesG03BA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.7 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the fluid retaining activities of Fluoxymesterone.
AcarboseFluoxymesterone may increase the hypoglycemic activities of Acarbose.
AcenocoumarolFluoxymesterone may increase the anticoagulant activities of Acenocoumarol.
AlbiglutideFluoxymesterone may increase the hypoglycemic activities of Albiglutide.
AlclometasoneAlclometasone may increase the fluid retaining activities of Fluoxymesterone.
AldosteroneAldosterone may increase the fluid retaining activities of Fluoxymesterone.
AlogliptinFluoxymesterone may increase the hypoglycemic activities of Alogliptin.
AmcinonideAmcinonide may increase the fluid retaining activities of Fluoxymesterone.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the fluid retaining activities of Fluoxymesterone.
BetamethasoneBetamethasone may increase the fluid retaining activities of Fluoxymesterone.
BromocriptineFluoxymesterone may increase the hypoglycemic activities of Bromocriptine.
BudesonideBudesonide may increase the fluid retaining activities of Fluoxymesterone.
C1 Esterase Inhibitor (Human)Fluoxymesterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Fluoxymesterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CanagliflozinFluoxymesterone may increase the hypoglycemic activities of Canagliflozin.
ChlorpropamideFluoxymesterone may increase the hypoglycemic activities of Chlorpropamide.
CiclesonideCiclesonide may increase the fluid retaining activities of Fluoxymesterone.
Clobetasol propionateClobetasol propionate may increase the fluid retaining activities of Fluoxymesterone.
ClocortoloneClocortolone may increase the fluid retaining activities of Fluoxymesterone.
Cortisone acetateCortisone acetate may increase the fluid retaining activities of Fluoxymesterone.
CyclosporineFluoxymesterone may increase the hepatotoxic activities of Cyclosporine.
DapagliflozinFluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the fluid retaining activities of Fluoxymesterone.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the fluid retaining activities of Fluoxymesterone.
DesoximetasoneDesoximetasone may increase the fluid retaining activities of Fluoxymesterone.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the fluid retaining activities of Fluoxymesterone.
DexamethasoneDexamethasone may increase the fluid retaining activities of Fluoxymesterone.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the fluid retaining activities of Fluoxymesterone.
DicoumarolFluoxymesterone may increase the anticoagulant activities of Dicoumarol.
DiflorasoneDiflorasone may increase the fluid retaining activities of Fluoxymesterone.
DifluocortoloneDifluocortolone may increase the fluid retaining activities of Fluoxymesterone.
DifluprednateDifluprednate may increase the fluid retaining activities of Fluoxymesterone.
DisopyramideFluoxymesterone may increase the hypoglycemic activities of Disopyramide.
DulaglutideFluoxymesterone may increase the hypoglycemic activities of Dulaglutide.
EmpagliflozinFluoxymesterone may increase the hypoglycemic activities of Empagliflozin.
EquileninEquilenin may increase the fluid retaining activities of Fluoxymesterone.
EquilinEquilin may increase the fluid retaining activities of Fluoxymesterone.
EstroneEstrone may increase the fluid retaining activities of Fluoxymesterone.
Ethyl biscoumacetateFluoxymesterone may increase the anticoagulant activities of Ethyl biscoumacetate.
ExenatideFluoxymesterone may increase the hypoglycemic activities of Exenatide.
FludrocortisoneFludrocortisone may increase the fluid retaining activities of Fluoxymesterone.
FlumethasoneFlumethasone may increase the fluid retaining activities of Fluoxymesterone.
FlunisolideFlunisolide may increase the fluid retaining activities of Fluoxymesterone.
Fluocinolone AcetonideFluocinolone Acetonide may increase the fluid retaining activities of Fluoxymesterone.
FluocinonideFluocinonide may increase the fluid retaining activities of Fluoxymesterone.
FluocortoloneFluocortolone may increase the fluid retaining activities of Fluoxymesterone.
FluorometholoneFluorometholone may increase the fluid retaining activities of Fluoxymesterone.
FluprednideneFluprednidene may increase the fluid retaining activities of Fluoxymesterone.
FluprednisoloneFluprednisolone may increase the fluid retaining activities of Fluoxymesterone.
FlurandrenolideFlurandrenolide may increase the fluid retaining activities of Fluoxymesterone.
Fluticasone furoateFluticasone furoate may increase the fluid retaining activities of Fluoxymesterone.
Fluticasone PropionateFluticasone Propionate may increase the fluid retaining activities of Fluoxymesterone.
GliclazideFluoxymesterone may increase the hypoglycemic activities of Gliclazide.
GlimepirideFluoxymesterone may increase the hypoglycemic activities of Glimepiride.
GlipizideFluoxymesterone may increase the hypoglycemic activities of Glipizide.
GlyburideFluoxymesterone may increase the hypoglycemic activities of Glyburide.
HydrocortisoneHydrocortisone may increase the fluid retaining activities of Fluoxymesterone.
Insulin AspartFluoxymesterone may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirFluoxymesterone may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineFluoxymesterone may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineFluoxymesterone may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanFluoxymesterone may increase the hypoglycemic activities of Insulin Human.
Insulin LisproFluoxymesterone may increase the hypoglycemic activities of Insulin Lispro.
LanreotideFluoxymesterone may increase the hypoglycemic activities of Lanreotide.
LiraglutideFluoxymesterone may increase the hypoglycemic activities of Liraglutide.
MecaserminFluoxymesterone may increase the hypoglycemic activities of Mecasermin.
MedrysoneMedrysone may increase the fluid retaining activities of Fluoxymesterone.
MelengestrolMelengestrol may increase the fluid retaining activities of Fluoxymesterone.
MetforminFluoxymesterone may increase the hypoglycemic activities of Metformin.
MethylprednisoloneMethylprednisolone may increase the fluid retaining activities of Fluoxymesterone.
MifepristoneFluoxymesterone may increase the hypoglycemic activities of Mifepristone.
MiglitolFluoxymesterone may increase the hypoglycemic activities of Miglitol.
MometasoneMometasone may increase the fluid retaining activities of Fluoxymesterone.
NateglinideFluoxymesterone may increase the hypoglycemic activities of Nateglinide.
OctreotideFluoxymesterone may increase the hypoglycemic activities of Octreotide.
ParamethasoneParamethasone may increase the fluid retaining activities of Fluoxymesterone.
PasireotideFluoxymesterone may increase the hypoglycemic activities of Pasireotide.
PentamidineFluoxymesterone may increase the hypoglycemic activities of Pentamidine.
PhenindioneFluoxymesterone may increase the anticoagulant activities of Phenindione.
PhenprocoumonFluoxymesterone may increase the anticoagulant activities of Phenprocoumon.
PioglitazoneFluoxymesterone may increase the hypoglycemic activities of Pioglitazone.
PramlintideFluoxymesterone may increase the hypoglycemic activities of Pramlintide.
PrednicarbatePrednicarbate may increase the fluid retaining activities of Fluoxymesterone.
PrednisolonePrednisolone may increase the fluid retaining activities of Fluoxymesterone.
PrednisonePrednisone may increase the fluid retaining activities of Fluoxymesterone.
PregnenolonePregnenolone may increase the fluid retaining activities of Fluoxymesterone.
QuinineFluoxymesterone may increase the hypoglycemic activities of Quinine.
RepaglinideFluoxymesterone may increase the hypoglycemic activities of Repaglinide.
RimexoloneRimexolone may increase the fluid retaining activities of Fluoxymesterone.
RosiglitazoneFluoxymesterone may increase the hypoglycemic activities of Rosiglitazone.
SaxagliptinFluoxymesterone may increase the hypoglycemic activities of Saxagliptin.
SitagliptinFluoxymesterone may increase the hypoglycemic activities of Sitagliptin.
SulfadiazineFluoxymesterone may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleFluoxymesterone may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleFluoxymesterone may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibFluoxymesterone may increase the hypoglycemic activities of Sunitinib.
TixocortolTixocortol may increase the fluid retaining activities of Fluoxymesterone.
TolazamideFluoxymesterone may increase the hypoglycemic activities of Tolazamide.
TolbutamideFluoxymesterone may increase the hypoglycemic activities of Tolbutamide.
TriamcinoloneTriamcinolone may increase the fluid retaining activities of Fluoxymesterone.
WarfarinFluoxymesterone may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Molecular Weight:
98987.9 Da
References
  1. Fernandez L, Chirino R, Boada LD, Navarro D, Cabrera N, del Rio I, Diaz-Chico BN: Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes. Endocrinology. 1994 Mar;134(3):1401-8. [PubMed:8119180 ]
  2. Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ: Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989 Mar;124(3):1576-8. [PubMed:2521824 ]
  3. Smallridge RC, Vigersky R, Glass AR, Griffin JE, White BJ, Eil C: Androgen receptor abnormalities in identical twins with oligospermia. Clinical and biochemical studies. Am J Med. 1984 Dec;77(6):1049-54. [PubMed:6439037 ]
  4. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. [PubMed:17023534 ]
  5. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM: Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999 Mar;13(3):440-54. [PubMed:10077001 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul;98(2):217-22. Epub 2006 Mar 15. [PubMed:16538529 ]
  2. Sledge GW Jr, Hu P, Falkson G, Tormey D, Abeloff M: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 2000 Jan;18(2):262-6. [PubMed:10637238 ]
  3. Pearson OH, Manni A, Arafah BM: Antiestrogen treatment of breast cancer: an overview. Cancer Res. 1982 Aug;42(8 Suppl):3424s-3429s. [PubMed:7044524 ]
  4. Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May;14(5):1589-98. [PubMed:8622076 ]
  5. Swain SM, Steinberg SM, Bagley C, Lippman ME: Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study. Breast Cancer Res Treat. 1988 Sep;12(1):51-7. [PubMed:3058238 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling.
Gene Name:
PRLR
Uniprot ID:
P16471
Molecular Weight:
69505.045 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Mayer M, Rosen F: Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. Am J Physiol. 1975 Nov;229(5):1381-6. [PubMed:173192 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Molecular Weight:
43778.755 Da
References
  1. Smallridge RC, Vigersky R, Glass AR, Griffin JE, White BJ, Eil C: Androgen receptor abnormalities in identical twins with oligospermia. Clinical and biochemical studies. Am J Med. 1984 Dec;77(6):1049-54. [PubMed:6439037 ]
  2. Pugeat MM, Dunn JF, Nisula BC: Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981 Jul;53(1):69-75. [PubMed:7195405 ]
  3. Vigersky RA, Easley RB, Loriaux DL: Effect of fluoxymesterone on the pituitary-gonadal axis: the role of testosterone-estradiol-binding globulin. J Clin Endocrinol Metab. 1976 Jul;43(1):1-9. [PubMed:947929 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23